# Progyny, Inc. Announces Share Repurchase Program
Canonical URL: https://biopharmsignal.com/news/PGNY/progyny-inc-announces-share-repurchase-program
Ticker: PGNY
Company: Progyny
Source: Progyny
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.progyny.com
## Summary

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock.

## Article Body
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock.
## Recent Company News
- 2026-06-25 13:46 EST — [New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System](https://biopharmsignal.com/news/PGNY/new-progyny-study-shows-growing-demand-for-human-guidance-in-an-increasingly-digital-healthcare-system) — Source: Progyny
- 2026-06-25 13:46 EST — [Progyny, Inc. Announces Share Repurchase Program](https://biopharmsignal.com/news/PGNY/progyny-inc-announces-share-repurchase-program) — Source: Progyny
- 2026-06-25 13:46 EST — [Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference](https://biopharmsignal.com/news/PGNY/progyny-inc-to-present-at-bofa-securities-2026-health-care-conference) — Source: Progyny
- 2026-06-25 13:46 EST — [Progyny, Inc. Announces First Quarter 2026 Results](https://biopharmsignal.com/news/PGNY/progyny-inc-announces-first-quarter-2026-results) — Source: Progyny
- 2026-06-25 13:46 EST — [Progyny, Inc. Announces Third Quarter 2025 Results](https://biopharmsignal.com/news/PGNY/progyny-inc-announces-third-quarter-2025-results) — Source: Progyny
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)